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Iron overload in renal failure patients: Changes since the intro- mias [4], including the anemia of chronic renal failure
duction of erythropoietin therapy. Iron overload was a common (CRF) [5–7] or from the repetitive injection of parenteral
complication in patients with chronic renal failure treated with iron. Hemosiderosis is also referred to as secondary irondialysis prior to the availability of recombinant human erythro-
overload.poietin (rHuEPO) therapy. Iron overload was the result of hypo-
Traditionally, hemochromatosis and hemosiderosis haveproliferative erythroid marrow function coupled with the need
for frequent red blood cell transfusions to manage symptomatic been separated by the concept that in the former, the
anemia. The repetitive use of intravenous iron with or without iron overload is primarily in tissue parenchymal cells
the use of red blood cell transfusions also contributed to iron leading to organ dysfunction and eventually organ fail-loading and was associated with iron deposition in liver paren-
ure, whereas in hemosiderosis, the iron is limited to thechymal and reticuloendothelial cells; however, there were no
RE cell, with no organ dysfunction or failure. However,abnormal liver function tests or evidence of cirrhosis unless viral
hepatitis resulted from the transfusions. With rHuEPO ther- in hemosiderosis, these lines of separation may not al-
apy, the excess iron stores were shifted back into circulating red ways be that precise, as noted in a review of iron overload
blood cells as the anemia was partially corrected, and red blood
in various conditions [8], particularly that of CRF [9].cells were lost from circulation by the hemodialysis procedure.
In order to appreciate the changes that recombinantAfter several years of rHuEPO therapy, most hemodialysis
patients required iron supplements to replace the continuing human erythropoietin (rHuEPO) has made on the iron-
blood losses related to hemodialysis. The potential complica- overload complication in CRF, it is important to under-
tions of iron overload (parenchymal iron deposition, perma- stand what impact, if any, iron overload has had on the
nent organ damage, increased risk of bacterial infections, and
overall health of dialysis patients.increased free radical generation) are reviewed in the context
of this setting.
IRON PHYSIOLOGY
The amount of iron in excess of normal iron storesIron stores in normal subjects vary between approxi-
required to develop hemosiderosis is not known, butmately 800 mg to 1200 mg, depending on body size [1],
probably is considerable. One estimate is that the storagealthough phlebotomy studies suggest that normal iron
limit of macrophages is exceeded after the accumulationstores may be as high as 1200 to 1500 mg [2]. Primary
of 5 g of unexcretable iron [8]. An understanding of ironiron overload, or primary hemochromatosis, is a common
transport and kinetics is essential in order to comprehendhereditary disorder in which excessive amounts of iron
the issue of “iron overload.” This is particularly trueare absorbed from the gastrointestinal tract, resulting
since the introduction of rHuEPO therapy, which hasover many years in the accumulation of massive amounts
changed our understanding of iron metabolism and itsof iron (as much as 20 to 40 g) in the parenchymal cells
management in CRF.of various tissues, leading to end-organ damage to the
Iron that is absorbed from the gastrointestinal tract isheart, liver, and pancreas [3]. Hemosiderosis is the accu-
transported in circulation to either the erythroid marrow,mulation of excess iron, primarily in the reticuloendothe-
RE cells, or various tissues (for example, myoglobin inlial (RE) cells of the liver, marrow, and spleen, as the
muscle cells or liver in severe iron overload) by theresult of the repetitive infusion of iron from red blood
protein transferrin. Iron that is injected intravenously,cell (RBC) transfusions for the treatment of severe ane-
either as RBCs or as an iron compound (iron dextran,
ferric gluconate, or ferric saccharate), is processed by
Key words: chronic renal failure, blood, rHuEPO, anemia, dialysis. the RE cell and then transported on one or both iron-
binding sites of the transferrin molecule to either the 1999 by the International Society of Nephrology
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erythroid marrow or to various other tissues. The likeli-
hood that nonerythroid tissues will take up transferrin-
bound iron is determined by the activity of the erythroid
marrow and by the degree of saturation of transferrin.
Transferrin receptors are probably expressed on all cells,
with the exception of mature RBCs, with the highest
expression of receptors on hemoglobin-synthesizing cells
[10]. One of the few ferrokinetic studies in hemodialysis
patients not treated with rHuEPO noted that the nonery-
throid iron turnover was directly related to serum iron
levels and with the percentage transferrin saturation,
with serum iron values of more than 150 mg/dl, and
transferrin saturations of more than 60% associated with
a nonerythroid iron turnover of more than 0.4 mg/100
ml whole blood/day (normal 5 0.16; Fig. 1). This suggests
that when the transferrin saturation is more than 60%
and the serum iron is greater than 150 mg/dl, the likeli-
hood of transferrin-bound iron being shunted to nonery-
throid cells is increased in the anemic dialysis patient
not treated with rHuEPO. In the anemic patient treated
with rHuEPO, erythropoiesis is stimulated, and more
iron will be preferentially taken up by the erythroid
marrow, reducing the likelihood of iron deposition in
Fig. 1. The amount of nonerythroid iron turnover in patients onnonerythroid tissues and mobilizing stored iron in order
chronic hemodialysis related to their serum iron values (A) and percent-
to support new hemoglobin synthesis. age transferrin saturation (B; unpublished observations).
IRON OVERLOAD IN CRF PRIOR TO
ERYTHROPOIETIN THERAPY administration in dialysis patients, iron deposition often
To appreciate the effect that rHuEPO treatment has occurred in the liver when erythroid marrow function
had on iron overload in anemic CRF patients, it is neces- was severely depressed [9]. Liver biopsies in these pa-
sary to understand what the experience was with iron tients disclosed iron in both hepatocytes and Kupffer
overload prior to the introduction of rHuEPO therapy. cells (the RE cell of the liver) [9]. Because of the persis-
Prior to the availability of rHuEPO therapy in CRF, tent anemia, RBC transfusions were often necessary.
iron overload was very common. The natural progression Gradually, as more RBC transfusions were given and
of the anemia of CRF results in a gradual shift of red iron intake exceeded iron losses, the transferrin satura-
cell iron into storage sites in the RE system (RES) so tion and serum ferritin levels increased, and as the trans-
that by the time patients start dialysis, if not treated with ferrin saturation rose, iron was delivered in increasing
rHuEPO, they are often severely anemic (hematocrit amounts to the liver and the parenchymal cells of other
15% to 25%/hemoglobin 5 to 8 g/dl). If external blood tissues, including heart, thyroid, and pancreas. This ulti-
losses have not occurred, then the iron, previously part mately led to evident tissue iron overload, as demon-
of the RBC mass, becomes sequestered in the RES, strated by bone marrow and liver biopsy and autopsy
resulting in elevated serum ferritin levels even in those studies [6, 7, 9, 12–19]. Some individuals eventually had
transferrin saturations and serum ferritin levels exceedingpatients who have not received any exogenous iron.
The anemia of CRF is primarily due to insufficient 80% and 4000 ng/ml, respectively. However, this was not
necessarily an irreversible process. Some dialysis patientsproduction of renal erythropoietin. Recently, erythro-
poietin has been shown to increase transferrin receptor had enough erythroid marrow function to not require
RBC transfusions and did not shunt unincorporatedsynthesis and cell surface expression in erythroid cells by
activating the iron regulatory protein 1, thus stabilizing RBC iron into the liver [9]. Occasionally, erythropoiesis
in some dialysis patients spontaneously improved [9],transferrin receptor mRNA [11]. Without sufficient eryth-
ropoietin stimulation of the erythroid cell, the number particularly if RBC transfusions were avoided. Red cell
transfusions in these patients had resulted in further sup-of erythroid cell surface transferrin receptors is probably
down-regulated, increasing the likelihood of iron uptake pression of the small amount of renal erythropoietin that
was being produced [20]. If, and when, erythropoiesisby nonerythroid tissues, including the liver.
As reflected by in vivo organ counting following 59Fe improved in these patients, iron overload gradually was
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reduced because of the elimination of RBC transfusions iron given as RBC transfusions may be a critical one. The
hemosiderosis from iron overload secondary to RBCcoupled with the ongoing blood losses related to the
hemodialysis procedure. Prior to rHuEPO therapy, there transfusions may be complicated by the presence of hep-
atitis B or C acquired in the course of being transfusedevolved the practice of not transfusing except when there
was symptomatic tissue hypoxia. Most patients without [16]. Hepatocellular injury from hepatitis C may favor
iron deposition in liver parenchymal cells [34]. Becauseangina could slowly adjust to a hematocrit of 22% to
28% and not require RBC transfusions, although energy serological testing for hepatitis C was not available dur-
ing the pre-rHuEPO era when RBC transfusions werelevels and quality of life were diminished.
Nevertheless, although hemodialysis-related iron common therapy for the anemia of CRF, it is difficult
to determine the relative contributions of hepatitis and(blood) losses were often large (1 to 3 g/year) [21–23],
these losses frequently did not compensate for the amount iron deposition to the abnormal liver biopsy/autopsy
findings and other liver tests performed.of iron previously received from RBC transfusions. There-
fore, iron overload persisted. Attempts to reduce iron Parenteral infusion of iron, in various forms, has been
studied extensively in animals. The amount of iron theseoverload with desferrioxamine were successful primarily
in those patients who no longer required RBC transfu- animals received in different studies ranged between 0.1
and 3.3 g/kg with a follow-up between four weeks andsions. However, in the majority of patients, the amount
of iron chelated and transferred across the dialyzer mem- seven years [35, 36]. Despite these large infusions of iron
(up to 17 g), the kind of parenchymal tissue changesbrane was less than the amount of iron received intrave-
nously through ongoing RBC transfusions [24–28]. Al- seen in primary hemochromatosis has not been observed;
that is, cirrhosis and pancreatic fibrosis have not beenthough no recent studies of dialyzer blood losses have
been published, we believe there are still substantial found, and tests of liver and cardiac function and of
glucose tolerance have remained normal. The largeiron losses occurring even with the newer dialyzers. For
instance, during 1994, 75% of the 615 hemodialysis pa- amounts of iron were predominantly sequestered in RE
tients at the Northwest Kidney Centers (Seattle, WA, cells without any fibrotic reaction present.
USA) received 0.5 to 3.0 g (1.0 6 0.6 g, mean 6 sd)
of iron dextran i.v., despite ingesting oral iron, just to
IRON OVERLOAD IN CRF SINCEmaintain serum ferritin levels and transferrin saturations
rHuEPO THERAPYclose to 100 ng/ml and 20%, respectively (J. W. Eschbach,
There are no good epidemiological data to indicateR. Garth, and C. R. Blagg, unpublished results).
the magnitude of iron overload prior to the availabilityIron overload also has occurred as the result of the
of rHuEPO, but it must have been common. Approxi-excessive administration of parenteral iron. Most studies
mately 50% of dialysis patients in one study requiredof iron overload in dialysis patients have included pa-
more than one RBC transfusion monthly [37]. One cen-tients who have received both parenteral iron as well as
ter noted that 64 of its 120 hemodialysis patients hadRBC transfusions [12, 14, 16, 17, 27, 29–31]. There has
serum ferritin levels of more than 1000 ng/ml [17]. Thebeen only one report of iron overload in dialysis patients
longer patients survived and were transfused, the greatercaused by intravenous iron infusions without any RBC
the likelihood that iron overload would develop.transfusions: Two groups of dialysis patients with iron
The introduction of rHuEPO has resulted in majoroverload were studied. One group received repeated
benefits for the patient with the anemia of CRF. One ofinjections of parenteral iron. The other group received
these has been the elimination of the need for routinemultiple RBC transfusions [32]. The serum ferritin levels
RBC transfusions and the eventual elimination of ironranged from just below 1000 ng/ml up to 3000 ng/ml in
overload. Many studies have demonstrated that serumthe parenteral iron group and less than 1000 ng/ml in
ferritin levels decrease abruptly with the use of rHuEPOthe transfused group. Although iron was present in both
in CRF [38–40], as well as in normal subjects [41]. Thishepatocytes and Kupffer cells on liver biopsies in some
results from the mobilization of storage iron for incorpo-patients, the authors did not attempt to determine if the
ration into newly synthesized hemoglobin. Further deple-liver cell iron deposition was different between the two
tion of iron stores occurs in the hemodialysis patient,groups. Iron overload also has been reported in a subject
particularly, because of continued dialyzer-related bloodwith normal renal function who received 52 g of elemen-
losses [21–23]. Several investigators have shown that irontal iron intramuscularly over a 20-year period for treat-
overload could be reduced more rapidly if periodic phle-ment of an ill-defined anemia [33]. The serum ferritin
botomy were performed in association with rHuEPOwas 2840 ng/ml, and liver function tests were normal.
therapy [13–15, 19]. We noted that of the original 23Despite the fact that liver biopsy disclosed large deposits
hemodialysis patients treated with rHuEPO [37], 17 wereof iron in the parenchyma with minimal iron deposition
still receiving rHuEPO three years later [42]. Many ofin the Kupffer cells, there was no cirrhosis.
The distinction between iron given parenterally and these patients originally had iron overload, as arbitrarily
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These concerns relate to the following possible complica-
tions: (a) parenchymal cell involvement with or without
organ dysfunction, (b) permanent organ damage, that is,
cirrhosis and/or pancreatic fibrosis, cancer, or myocardial
infarction, (c) increased risk of bacterial infections, and
(d) increased free radical generation from free iron caus-
ing increased oxidant-mediated tissue injury. None of
these concerns has been proven, but because iron ther-
apy is so essential to the optimum effectiveness of
rHuEPO, it is appropriate to review these concerns in
relation to the extensive degree of iron overload in the
pre-rHuEPO era and whether these complications might
develop today if the use of intravenous iron were more
routine and poorly monitored.
Parenchymal iron deposition
In one report of chronically anemic adults with normal
renal function, multiple RBC transfusions resulted in
iron overload. These patients had evidence of hepato-
megaly with iron in both the hepatocytes and Kupffer
cells on liver biopsy [4]; however, cirrhosis was not ob-
served except in one patient with a prior history of hepa-
titis. A similar pattern was observed in another anemic
Fig. 2. Decline in serum ferritin levels during three to four years of subject (with normal renal function) who received exces-
rHuEPO therapy in 17 hemodialysis patients [42]. Symbols are: (s) sive amounts of intramuscular iron [33]. Cirrhosis alsoiron excess, N 5 6; (d) normal stores, N 5 11.
failed to develop after chronic parenteral iron adminis-
tration to dogs, although the iron deposits were localized
in the RE cells and not the parenchyma [35]. Iron over-
load in hemodialysis patients has resulted in increaseddefined by a serum ferritin of more than 1000 ng/ml
iron deposition in liver parenchymal cells as well as the(mean 6 sd serum ferritin 1073 6 956 ng/ml). After
Kupffer cells [9]. Cirrhosis was observed primarily inthree years of rHuEPO therapy, all 17 had normal or
iron-overloaded patients who had a history of hepatitislow serum ferritin levels (186 6 196 ng/ml; Fig. 2), and
B, or perhaps hepatitis C, but there was no way to docu-15 required supplemental iron therapy [41]. Today, very
ment the latter disease at that time.few dialysis patients have iron overload unless they con-
Iron overload in hemodialysis patients has also beentinue to require RBC transfusions and/or are unable to
associated with a proximal myopathy [45]. Ten patientsbe treated with rHuEPO.
had proximal muscle weakness and serum ferritin levelsIron deficiency is now far more common than iron over-
of 1030 to 5000 ng/ml. Proximal muscle biopsies (in sevenload as a result of the combined significant dialyzer-related
of 10 patients) disclosed iron deposition in muscle fibersblood losses and the stimulating effect of rHuEPO on
(five of seven) and macrophages (six of seven). However,hemoglobin synthesis. As recently as 1996, the United
there was no evidence of muscle injury or inflammation,States Renal Disease System’s Dialysis Morbidity and
and the amount of iron deposition did not correlate withMortality Study noted that more than 50% of 2613 dial-
the severity of muscle weakness. All of these patientsysis patients in 1993 had transferrin saturation values of
had one or more of the “hemochromatosis alleles,” thatless than 20%, and 36% had serum ferritin levels of less
is, HLA3, B7, or B14. The authors suggested that pa-than 100 ng/ml [43]. Because of the need to correct iron
tients with the hemochromatosis alleles are at increaseddeficiency and to maintain iron stores in the dialysis
risk to develop iron overload and muscle iron deposition.patient treated with rHuEPO, iron supplementation is
Because primary hemochromatosis is a very commonrequired, and iron given intravenously accomplishes this
inherited metabolic disorder (1 in 300 whites being ho-task much better than does oral iron [40].
mozygous and 1 in 10 being heterozygous) [46], it would
be expected that among the thousands of dialysis pa-
ADVERSE EFFECTS OF CHRONIC IRON tients, many would either have the disease or be a carrier
OVERLOAD IN CRF of the gene for this disorder. One theory is that these
There has been much concern raised about the poten- patients would lack the regulatory mechanism that pre-
vents iron absorption in the presence of adequate irontial toxicity of chronic iron exposure in dialysis patients.
Eschbach and Adamson: Iron overload in renal failure S-39
stores, and this would result in the preferential deposi- there was a statistically significant difference in the pre-
viously mentioned iron values between those men whotion of iron in parenchymal cells, rather than the RES.
A report from Italy suggested that dialysis patients that did or did not develop cancer, the biological significance
of these differences must be questioned (transferrin satu-had one or more of these three hemochromatosis alleles
were more prone to develop iron overload from RBC ration 33.1% vs. 30.7%; total iron-binding capacity 61.4
mmol/liter vs. 62.9 mmol/liter).transfusions than those patients without any of these
HLA antigens [47]. However, another report failed to
Increased risk of bacterial infectionsconfirm a correlation between the presence of hemo-
chromatosis alleles in CRF and iron overload [48]. There There is concern that iron overload promotes the pro-
liferation of microorganisms. In vitro, free elemental ironare a number of problems with this concept: (a) Only
one center has reported excess iron in muscle cells, and is a growth factor for bacteria. Although free iron has
been assumed to be present in iron overload states, thereeven that study noted that the myopathy was out of
proportion to the amount of iron present. (b) Myopathy is no evidence to support this assumption. There is no
free iron in circulation as long as transferrin is less thanis not a prominent complication of primary hemochro-
matosis or hemosiderosis in nondialysis patients, and fully saturated. Most dialysis patients of 20 to 30 years
ago who had iron overload had transferrin saturations(c) patients heterozygous for hemochromatosis do not
absorb excessive amounts of iron. of less than 95%, and it is rare for the parenteral iron-
treated patient to have a transferrin saturation chroni-
Permanent organ damage cally greater than 50%. Nevertheless, an increased inci-
dence of infections has been reported in dialysis patientsIn dialysis patients with hemosiderosis, there have
been no reports of cirrhosis, pancreatic fibrosis, or car- with iron overload [52–55]. This has been assumed to be
due to the suppression of phagocytosis by iron as studieddiac failure caused by iron overload. Cirrhosis is seen in
patients with hepatitis B or C. Pancreatic fibrosis may be in vitro [56–58]. Seifert et al noted that 10 hemodialysis
patients with serum ferritin levels of 1001 to 2000 ng/ml,seen in patients with insulin-dependent diabetes mellitus,
and cardiac failure may occur in patients with coronary caused by multiple RBC transfusions and not treated
with desferrioxamine, had a significantly increased inci-artery disease, hypertensive cardiovascular disease, or
other cardiomyopathies unrelated to iron overload. All dence of bacterial infections when compared with 125
“control” hemodialysis patients whose serum ferritin lev-of these complications are common in the dialysis popu-
lation and are not necessarily related to iron overload. els were 10 to 330 ng/ml (P , 0.01) [52]. Sixteen other
hemodialysis patients treated with desferrioxamine, whoseIn view of the common prevalence of the gene associated
with primary hemochromatosis, there must be many dial- mean serum ferritin level exceeded 3000 ng/ml (range
1856 to 6112 ng/ml), also had a significantly increasedysis patients who are at risk to exhibit findings of this
disorder eventually. Perhaps the constant blood loss of incidence of bacterial infections compared with the “con-
trol” group mentioned earlier here (P , 0.01). No Yer-the hemodialysis procedure prevents the development
of the organ failure associated with primary hemochro- sinia infections were noted. Fourteen of these 16 patients
were women over 60 years of age. The authors emphasizematosis. Whether the administration of intravenous iron,
rather than oral iron, will result in an earlier unmasking that the serum ferritin levels were calculated by taking
the mean of several measurements throughout theirof this disorder remains to be determined.
A report from Finland suggested that excess dietary study period when no active infection was present, thus
avoiding spurious elevations due to infection per se. How-and body iron was a risk factor for myocardial infarction
[49]. This report has been subsequently contradicted by ever, the inflammatory effect on serum ferritin levels
may persist beyond the period of active infection, anda large study from the United States that concludes that
higher transferrin-saturation levels are not associated the immunologic suppressive effects of multiple RBC
transfusions could account for the increased susceptibil-with an increased risk of coronary artery disease [50]. The
Finnish study used only serum ferritin levels as a marker ity to infections.
A second study claiming that iron overload is a riskfor iron status, which may be inaccurate because ferritin
is also an acute phase reactant and could be falsely ele- factor for bacterial infections in dialysis patients [53]
noted that the most significant factors were a previousvated in the presence of inflammation or infection.
Cancer was more likely to develop in men, but not history of infection and the presence of a “central” ve-
nous catheter. An elevated serum ferritin, particularlywomen, when iron stores were elevated as determined
by a statistically significantly lower total iron-binding greater than 500 ng/ml, was also considered a risk factor
for infection, but not as statistically significant (P 5capacity and higher transferrin saturation [51]. However,
serum ferritin levels were not measured. The authors 0.028) as the first two risk factors (P , 0.0001 for both
prior infection and the presence of a central venous dial-assumed that there was an inverse relationship between
total iron-binding capacity and serum ferritin. Although ysis catheter); the mean 6 sd serum ferritin was 521 6
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775 ng/ml for those with infections (N 5 118) versus ferrin). (A single report in dialysis patients claimed that
the amount of “free” iron was greater in patients whose376 6 529 ng/ml for those without infection (N 5 489).
Although the differences in serum ferritin levels between serum ferritin exceeded 500 ng/ml [60]. However, there
was no correlation between such levels and an increasedthe two groups may be statistically significant, it does
not appear to be biologically significant in view of the incidence of infection.) The mean transferrin saturation
value was 70 6 6% prior to and 62 6 6% after approxi-large standard deviation and considerable overlap in the
values between groups. These authors have recently pub- mately 16 months of desferrioxamine therapy. Whether
binding of “free” iron by desferrioxamine is the reasonlished a prospective study on the risk factors for bacter-
emia in hemodialysis patients. There was no difference for the decreased incidence of infections in these dialysis
patients with iron overload is debatable. Because trans-between the group with bacteremia and those without
bacteremia as to the serum ferritin level, nor the inci- ferrin was not completely saturated, it is difficult to know
whether there was “free” iron in circulation.dence of iron therapy in the previous six months [59].
A third prospective study reported that the incidence A different study by Kessler et al concluded that bac-
teremia was more likely in patients with serum ferritinof bacteremia was 2.92 times higher in hemodialysis pa-
tients whose serum ferritin exceeded 1000 ng/ml com- levels of more than 1000 ng/ml, yet this was true for only
12 of 55 patients, whereas the majority of the bacteremicpared with those with lower serum ferritin levels [54].
There was no difference in the incidence of bacteremia (56%) and nonbacteremic (72%) patients had serum
ferritin levels of less than 500 ng/ml [62].in those with serum ferritin levels of 500 to 1000 ng/ml
versus those with serum ferritin levels of less than 500 There are a number of in vitro studies indicating that
iron suppresses neutrophil function [56–58, 62]. Phago-ng/ml. Serum ferritin levels also correlated significantly
with the number of RBC transfusions given. Of the 98 cytic function was noted to be better in 19 hemodialysis
patients with serum ferritin levels more than 1000 ng/mlpatients studied, bacteremia was documented 29 times
in 20 patients, eight of whom had ferritin levels of more (13 to 950 ng/ml) than in 21 chronically transfused pa-
tients with serum ferritin levels of more than 1000 ng/mlthan 1000 ng/ml. Fourteen patients had 17 episodes of
bacteremia associated with serum ferritin levels of less (range 1000 to 14,370 ng/ml; median 3770 ng/ml) [56].
Phagocytosis was assumed to be dysfunctional becausethan 1000 ng/ml (2 patients had bacteremia at both serum
ferritin levels greater and less than 1000 ng/ml). Despite superoxide anion production by polymorphonuclear leu-
kocytes (PMN) after in vitro stimulation with opsonizedmore bacteremic episodes occurring in those with serum
ferritin levels less than 1000 ng/ml, the incidence/patient zymosan was less than in normal controls or those hemo-
dialysis patients with serum ferritin levels of less thanyears of dialysis was 2.92 times greater in those with
serum ferritin levels of more than 1000 ng/ml. There 1000 ng/ml. Although the differences were statistically
significant, there was much overlap between the twowere no differences between the groups of patients in the
types of microorganisms identified. Presumably, most, if groups of dialysis patients. Another study [57] noted
that 91 patients with iron overload from multiple RBCnot all, of these patients were anemic, but no data were
presented. rHuEPO was given to some of the patients transfusions (mean serum ferritin 1901 6 1044 ng/ml)
had decreased PMN phagocytosis as quantitated by thelater in their follow-up, but no information is available
about the rates of infection in these patients. amount of Yersinia enterocolitica ingested compared
with 91 hemodialysis patients with a mean serum ferritinA fourth study of 61 patients reported that there was
a significant increase in bacterial infections and sepsis of 122 6 100 ng/ml. Although the authors attribute the
increased incidence of bacterial infections in hemodialy-in 18 hemodialysis patients whose serum ferritin levels
exceeded 500 ng/ml [55]. When 26 patients with a ferritin sis patients to iron overload, there are two reasons to
question their conclusion: The incidence of bacterial in-of less than 500 ng/ml were compared with 26 whose
ferritin levels were more than 500 ng/ml, the numbers fections in the group with iron overload was not stated,
and the liver enzyme activity was greater in that group,of infections were 1 versus 12, respectively (P , 0.005),
and septicemias 1 versus 7, respectively (P , 0.005). suggesting associated hepatitis.
A recent study reported that various in vitro tests ofHowever, when another group of 21 patients with iron
overload was treated for aluminium intoxication with the neutrophil function, particularly intracellular killing and
the neutrophil oxidative burst, were more impaired iniron chelater, desferrioxamine, the incidence of infection
decreased significantly, yet the serum ferritin levels eight hemodialysis patients whose serum ferritin levels
were more than 650 ng/ml (911 6 69 ng/ml, mean 6(mean 6 sem) did not decline (2493 6 219 ng/ml to 2293 6
254 ng/ml). However, when desferrioxamine therapy was sem) than in patients with lower serum ferritin levels
[62]. This impairment in neutrophil function was similarstopped, the incidence of infection rose, whereas the
serum ferritin levels changed little (2444 6 103 ng/ml). to that observed in a group of patients with myelodys-
plastic syndrome who had secondary iron overload fromThe authors suggested that the benefit of desferrioxa-
mine was to bind “free” plasma iron (not bound to trans- RBC transfusions. Myelodysplastic patients are known
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to have an increased incidence of infections, whereas microorganisms [68]. However, there remains the theo-
retical concern that if free iron occurs, it can be reversiblypatients with primary hemochromatosis do not; however,
the latter group also had in vitro abnormalities in neutro- oxidized or reduced, making it potentially hazardous
because of its ability to participate in the generation ofphil function in this study. The authors assumed the
dialysis patients with neutrophil dysfunction had func- powerful oxidant species, such as the hydroxyl radical,
thus causing cellular injury. However, in vivo, most oftional iron deficiency, however, chronic inflammation
was not ruled out. The eight patients received 10 mg of the iron is bound to heme or nonheme proteins (that is,
myoglobin or transferrin) and does not directly catalyzeiron i.v. with each dialysis, making it unlikely that they
had functional iron deficiency and raising the possibility the generation of hydroxyl radicals or other oxidants
[69]. An exception to this has been the observation thatthat they had an inflammatory disorder to account for
the high serum ferritin and the low transferrin saturation cisplatin-induced acute renal failure in rats may be medi-
ated by free iron [70]. It is difficult to ascertain from thelevels. Furthermore, the clinical relevance of these find-
ings is difficult to assess, as these patients did not have records of those dialysis patients with severe transfusion-
induced iron overload whether they exhibited evidenceiron overload. The transferrin saturation values were
low (15.6 6 3.7%, mean 6 sem), which argues against of tissue injury from iron overload, in contrast to that
related to hepatitis.any “free” iron available to increase the likelihood of
infection. In summary, iron overload in the pre-rHuEPO era
was a serious problem with hepatosplenomegaly, hypers-Although the previously mentioned studies—most
of which were conducted prior to the routine use of plenism, and hyperpigmentation commonly seen. How-
ever, unless chronic hepatitis with cirrhosis developedrHuEPO—suggest an association between iron overload
and bacterial infections, factors other than iron overload as a result of transfusion-transmitted infection, there are
insufficient data to conclude that these patients had moremay explain this association. Only 12% of patients with
idiopathic hemochromatosis die with pneumonia [63], serious bacterial infections or had an increased mortality
compared to patients without iron overload. rHuEPOwhich is an incidence that is lower than the 15.5% infec-
tious mortality in United States dialysis patients (who therapy, with correction of the chronic anemia, has
greatly reduced the need for transfusions and hence thepresumably did not have associated iron overload) for
1996 [64]. Whether the increased incidence of bacterial likelihood of iron overload. There are no data that iron
overload from medicinal iron increases patient morbidityinfections is due to iron overload or immunosuppression
from established cirrhosis or diabetes mellitus in hem- or mortality. The use of more intravenous iron to replace
ochromatosis is difficult to determine. Thalassemia is iron (blood) losses associated with the hemodialysis pro-
associated with severe iron overload from RBC transfu- cedure, and to maintain optimal iron stores should not
sions. Infections appear to occur mainly in those patients pose a threat for the development of iron overload as
having had a splenectomy [63]. long as the patient’s iron status is monitored on a regular
Anemia (hemoglobin of less than 9.9 g/dl) is associated basis.
with a greater incidence of infection [63], and rHuEPO
Reprint requests to Joseph W. Eschbach, M.D., Minor and Jamesreverses the PMN dysfunction in dialysis patients with
Medical, 515 Minor Avenue, Seattle, Washington, 98104, USA.iron overload [65, 66]. In the latter study, the hematocrit
was not stated, and the reversal in PMN dysfunction
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